(B3) Biosimilar Operational Readiness: Current and Future Market Landscape

Biologics, used for decades to treat chronic inflammatory conditions, have substantially improved patient outcomes. While incredibly valuable, they are also a significant proportion of health care spend in the United States. Many biologics for rheumatology and chronic inflammatory diseases will lose patent protection over the next three years, a move analysts predict will precipitate a substantial shift in this expanding global market valued at $382 billion in 2022.

Biosimilars, “highly similar to” and without “clinically meaningful differences from” the reference biologic agents, are expected to decrease the overall cost burden to the health care system. Initial trends indicate relatively slow adoption of biosimilars, with more encouraging utilization of these products compared to reference biologics since 2020.Attention now shifts to considerations for a competitive market. Payers, stakeholders in adopting biosimilars, need education on biosimilar concepts, policies and regulations, clinical evidence, and market trends to prepare and provide timely access to newly launched and pipeline treatment options.

This session will discuss the current state of biosimilars and what to expect in the future.